87 results about "Primary biliary cirrhosis" patented technology

The invention relates to a preparation method and application of a sulfonylurea compound and a composition containing the same component as FXR and / or TGR5 agonist, the FXR and / or TGR5 agonist is a compound shown as a formula (I), or a pharmaceutically acceptable salt, a solvate, a prodrug, an isomer and a stable isotope derivative thereof. The compounds can be used for treatment of FXR and / or TGR5 mediated diseases including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity and other field.

The invention relates to a compound shown as formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof. R1, R2, R3, R4, m, n, W, A, Z, E, F, X and Y are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations and application in drugs for treatment and/or prevention of FXR (farnesoid X receptor) mediated nonalcoholic fatty liver diseases, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications, malignant tumors and other related diseases. (formula (I)).

The invention relates to a compound shown as formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof. R1, R2, R3, R4, m, n, W, A, Z, E, F, X and Y are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations and application in drugs for treatment and/or prevention of FXR (farnesoid X receptor) mediated nonalcoholic fatty liver diseases, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications, malignant tumors and other related diseases. (formula (I)).

The invention relates to preparation methods of sulphonylaminocarbonyl derivatives and compositions containing the same component and a use of the sulphonylaminocarbonyl derivatives as FXR and/or TGR5 agonists; the agonists are the sulphonylaminocarbonyl derivatives represented by the formula I, or pharmaceutically acceptable salts, prodrugs, solvates, hydrates, polymorphs, isomers, and stable isotope derivatives thereof. The compounds can be used for treatment of diseases and symptoms mediated by FXR and/or TGR5 and other therapeutic fields, wherein the diseases and symptoms include primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity.

The invention discloses a SNP in KRT8 gene exon area and determination method thereof, and the SNP locus with G/T polymorphisms (GG) is at 12563 site of the eighth exon area of the KRT8 gene and has nucleotide sequences SEQ ID NO:1 and SEQ ID NO:2. The invention also provides a determination method of the SNP locus, and research and development of the polymorphisms can be applied to researches in the aspect of primary biliary cirrhosis, for example, control of primary biliary cirrhosis attack and hepatic cirrhosis degree or improvement of liver transplantation success rate.

The invention discloses a method for breeding IL-12p40 (-/-) IL-2R alpha (-/-) mice used as novel hepatic fibrosis and primary biliary cirrhosis animal models. The method includes steps of (1), performing cross breeding on IL-2R alpha (+/-) mice and IL-12p40(-/-) mice to obtain IL-12p40(+/-) IL-2R alpha (+/-) mice by means of breeding; (2), performing cross breeding on IL-12p40(-/-) mice and the IL-12p40(+/-) IL-2R alpha (+/-) mice obtained in the step (1) to obtain IL-12p40(-/-) IL-2R alpha (+/-) mice by means of breeding; (3), performing inbreeding on the IL-12p40(-/-) IL-2R alpha (+/-) mice obtained in the step (2) and obtaining the identified IL-12p40(-/-) IL-2R alpha (-/-) mice. The method has the advantages that IL-12p40 is an important cell factor in the immune system of a patient, and functions and differentiation of CD4+T and CD8+T cells can be affected by the IL-12p40; IL-2R alpha is an alpha chain of an IL-2 receptor and plays a key role in keeping the balance of the immune system of the patient.

The invention discloses a Chinese medicine composition for treating an autoimmune liver disease. The Chinese medicine composition is prepared from the Chinese medicinal materials, namely rheum officinale, radix rubiae, fructus forsythia, herba siegesbeckiae, large-leaved gentian and liquorice. The invention also discloses a preparation method of the Chinese medicine composition and application of the Chinese medicine composition. The composition has the effects of clearing away heat and toxic materials, smoothing liver-gallbladder, and promoting blood circulation to remove blood stasis, and is mainly used for treating autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.

The invention belongs to the technical field of medicines, and particularly relates to a compound as shown in the formula (I), and pharmaceutically acceptable salt and ester or a stereisomer thereof.R1, R2, R3, M1, M2, m, n, Q, L, ring A, ring B and ring C are as defined in the specification. The invention further relates to a preparation method of the compounds, and application in preparing medicines for treating and/or preventing related diseases such as non-alcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorders, diabetic complication and malignant tumors mediated by an FXR. The formula (I) is shown in the description.

The present invention relates, first, to the discovery, identification, and characterization of novel nucleic acid molecules, that are associated with PBC, Sjögren's syndrome, scleroderma, SLE, autoimmune thyroiditis and various other connective tissue disorders. The novel nucleotide sequences of the present invention are retroviral in origin and are indicative of a PBC retrovirus which bears a strong correlation with PBC. The present invention is based, in part, on the Applicant's data which is the first evidence to suggest that PBC patient's tissue may harbor a transmissible agent. The association of a retroviral infectious agent with PBC was first demonstrated by Applicants in vitro by co-culture of periportal lymph nodes derived from patients at time of transplantation and healthy biliary epithelium cells. The Applicant's discoveries as described herein, report the characterization of PBC-associated infectious agent as retroviral as demonstrated by electron microscopy and immunoblot reactivity. In addition, Applicants have characterized novel nucleotide sequences which are associated with the PBC-associated retrovirus.

A method or composition comprising an anti-CD3 immune molecule for treatment of PSC (primary sclerosing cholangitis) or PBC (primary biliary cirrhosis) in a subject.

The invention discloses a colloidal gold chromatography anti-SSB antibody detection test paper and a preparation method thereof. The colloidal gold chromatography anti-SSB antibody detection test paper comprises a sample pad, a combination pad, a cellulose nitrate coated film and a water absorption pad, and the sample pad, the combination pad, the cellulose nitrate coated film and the water absorption pad are pasted on a base plate sequentially from one side of the base plate to the other side of the base plate, wherein the combination pad is coated with a gold-labeled antibody a and a gold-labeled antibody b; and the cellulose nitrate coated film is provided with a detection line and a quality control line, the detection line is coated with an SSB antigen protein, and the quality control line is coated with a gold-labeled antibody c. By adopting indirect immunoassay to introduce the SSB antigen protein in the invention to carry out process optimization on the combination pad and the sample pad, so high sensitivity, high specificity and high accuracy detection performances of the anti-SSB antibody are realized, and a reference basis is provided for the auxiliary diagnosis of primary biliary cirrhosis.

Disclosed is a therapeutic agent for primary biliary cirrhosis, which contains L-alanine or a pharmaceutically acceptable salt thereof as the active ingredient. The effect of this therapeutic agent is to reduce serum total bilirubin and transaminase value, thereby effectively curing primary biliary cirrhosis. This therapeutic agent can be chronically administrated for a long period of time and exhibits an effect superior to that obtained in ordinary medical therapy.

The invention discloses an efficient amplifying and culturing method for biliary epithelial cells in rabbit livers and belongs to the technical field of biological medicines. The efficient amplifying and culturing method comprises the following steps of: (1) separating, purifying and culturing the epithelial cells; (2) detecting cell growth lines; and (3) identifying the epithelial cells. The efficient amplifying and culturing method for the biliary epithelial cells, disclosed by the invention, has the advantages as follows: through a multi-step separating method, biliary epithelial cells with higher purities are obtained and a long-time multiplication culturing system for the biliary epithelial cells is established; a fact that the multiplication of the biliary epithelial cells in the livers can be obviously promoted through an Rho kinase inhibitor Y-27632 is first found; and the efficient amplifying and culturing method for the biliary epithelial cells, disclosed by the invention, has the advantages of simpler operation and the like, is suitable for promotion and application and can provide a platform for researches on a plurality of disease mechanisms including biliary atresia, primary biliary cirrhosis and the like.

The invention discloses a specific autoantigen EIF2C1 of primary biliary cirrhosis (PBC). According to the specific autoantigen of PBC and the application thereof, six novel autoantigens of PBC are obtained through screening; during the detection on the blood serum of a PBC patient, the positive rate of each autoantigen reaches over 15%, so that the new-found autoantigens are potential biomarkers which are used for accurately diagnosing PBC through distinguishing other autoimmune diseases.

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

The invention belongs to the technical field of medicines, and particularly relates to a compound as shown in the formula (I), and pharmaceutically acceptable salt and ester or a stereisomer thereof.R1, R2, R3, R4, W, A, Z, E, X, Y and n are as defined in the specification and the claims. The invention further relates to a preparation method of the compounds, pharmaceutical preparation and application in preparing medicines for treating and/or preventing related diseases such as non-alcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorders, diabetic complication andmalignant tumors mediated by an FXR. The formula (I) is shown in the description.

The invention discloses a traditional Chinese medicine for treating primary biliary cirrhosis and a preparation method and application of the traditional Chinese medicine. The traditional Chinese medicine comprises the following raw materials in parts by weight: 500-1500 parts of oriental wormwood, 1000-2500 parts of roots of common peony, 500-1000 parts of scorpio, 1000-2000 parts of cortex dictamni, 1000-2500 parts of malt and 500-2000 parts of licorice roots. The traditional Chinese medicine disclosed by the invention has the main effects of clearing heat and removing toxin, soothing livers and dispersing gallbladder as well as activating blood and removing stasis, is capable of treating overlap syndromes of primary biliary cirrhosis caused by endoretention of damp heat, liver and gall stasis and Qi-stagnancy and blood stasis, and is simple in composition formula, outstanding in medicinal effect, free of toxic or side effect and convenient to prepare.

The invention discloses a colloidal gold chromatography anti-Sp100 antibody detection test paper and a preparation method thereof. The colloidal gold chromatography anti-Sp100 antibody detection test paper comprises a sample pad, a combination pad, a cellulose nitrate coated film and a water absorption pad, and the sample pad, the combination pad, the cellulose nitrate coated film and the water absorption pad are pasted on a base plate sequentially from one side of the base plate to the other side of the base plate, wherein the combination pad is coated with a gold-labeled antibody a and a gold-labeled antibody b; and the cellulose nitrate coated film is provided with a detection line and a quality control line, the detection line is coated with an Sp100 antigen protein, and the quality control line is coated with a gold-labeled antibody c. By adopting indirect immunoassay to introduce the Sp100 antigen protein in the invention to carry out process optimization on the combination pad and the sample pad, so high sensitivity, high specificity and high accuracy detection performances of the anti-Sp100 antibody are realized, and a reference basis is provided for the auxiliary diagnosis of primary biliary cirrhosis.

The present invention discloses an FXR receptor agonist, belongs to the technical field of medicine, and particularly relates to a compound represented by a formula (I), a pharmaceutically acceptablesalt, an ester or a stereoisomer thereof, wherein R<1>, R<2>, R<3>, M, L, L1, W, A , B, Q, m and n are defined in the specification. The present invention further relates to a preparation method of the compound, a pharmaceutical preparation, and applications in preparation of drugs for treatment and/or prevention of nonalcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorder, diabetic complication, malignant tumors and other related diseases mediated by FXR receptors. The formula I is defined in the specification.

The invention relates to a traditional Chinese medicine for treating primary biliary cirrhosis, which is prepared from the following medicinal materials in parts by weight: 12 parts of fructus rosae laevigatae, 14 parts of radix scrophulariae, 6 parts of euphorbia jolkinii, 10 parts of beggarweed, 12 parts of climbing entada, 14 parts of elsholtzia rugulosa hemsl, 10 parts of michelia champaca, 14 parts of radix bupleuri, 10 parts of semen cassiae, 8 parts of rhizoma cyperi, 14 parts of semiliquidambar cathayensis, 10 parts of abutilon peniculatum flower, 14 parts of dysosma difformis, 12 parts of osbeckia chinensis, 14 parts of penthorum chinense pursh, 10 parts of twisted-stalk, 8 parts of all-grass of winkled marshweed, 10 parts of bryoniifolia root and 10 parts of gynura divaricata. Clinical tests prove that the traditional Chinese medicine disclosed by the invention can safely and effectively treat primary biliary cirrhosis.

The invention provides a method for analyzing primary biliary cirrhosis metabolites based on H1NMR technology, belongs to the field of biotechnology, and relates to primary biliary cirrhosis. The invention mainly comprises the following flow: step 1, sample collection and preparation, liver function testing; step 2, extraction, alignment, and normalization of original data; step 3, primary component analysis (PCA); step 4, orthogonal partial least squares-discriminant analysis (OPLS-DA); step 5, searching of metabolites causing intergroup differences; steo 6, statistical test. The advantages of the invention are that: the analysis method provided by the invention provides a new approach and method for the analysis research of primary biliary cirrhosis metabolites; the method has reasonable and feasible design, provides new landmarks for the research of the diagnosis and treatment of PCB, and also provides new thoughts for the research of the pathogenesis.

The invention belongs to the technical field of medical biology, in particular to a preparation method of high-purity natural ursodesoxycholic acid. The high-purity natural ursodesoxycholic acid is obtained by separating and purifying bear gall powder prepared from a manual drained bear gall, and the high performance liquid chromatography purity is not lower than 98 percent. The preparation method comprises the following steps of: firstly, separating and purifying by applying a cation exchange medium to prepare tauroursodeoxycholic acid with purity not lower than 90 percent; and then thoroughly hydrolyzing the tauroursodeoxycholic acid into ursodesoxycholic acid and taurine in the presence of alkali and separating and purifying by applying a silica gel adsorption chromatography technology to prepare the ursodesoxycholic acid with purity not lower than 98 percent. The natural ursodesoxycholic acid prepared by the invention has the effects on treating primary biliary cirrhosis and primary sclerosing cholangitis.

Disclosed are deuterated chenodeoxycholic acid derivatives and pharmaceutical compositions containing the deuterated chenodeoxycholic acid derivatives. In particular, disclosed is a deuterated chenodeoxycholic acid derivative of formula (I), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the same. The deuterated chenodeoxycholic acid derivatives of formula (I) can be used to treat and/or prevent diseases related to the farnesoid X receptor (FXR) and/or G-protein coupled bile acid receptor, such as nonalcoholic steatohepatitis, nonalcoholic fatty liver diseases, gallstones, primary biliary cirrhosis, and cirrhosis.